PR Newswire PharmaOriginal article
HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
Phase 2positiveHBM9378/WIN378Positive
AI Analysis
Summary
HBM9378/WIN378, an ultra-long-acting TSLP-targeting antibody, achieved positive Phase 2 results in the POLARIS-1 study demonstrating a 75-day half-life supporting twice-yearly dosing in moderate-to-severe asthma patients, with Phase 3 initiation underway.
Clinical Trial Data
Phase
2
Primary Endpoint
Met
Patients
98
Outcome Details
Half-life of up to 75 days with clinical effects consistent with twice-yearly dosing in 98 patients with uncontrolled, moderate-to-severe asthma
Importance:7/10
Sentiment:
0.85
Phase 2AsthmaAntibodyTSLPUltra-Long-ActingPhase 3 Initiation
Read the original article
Published by PR Newswire Pharma on September 8, 2026 12:17 PM